Results 191 to 200 of about 67,273 (233)

Portraits of clonal hematopoiesis in DNMT3A/TET2/ASXL1-mutant myelodysplastic neoplasms and acute myeloid leukemia. [PDF]

Ann Hematol
Patel SA, Khedr S, Hutchinson L, Xie Y, Khouri MR, Cerny J, Gerber JM.   +6 more
europepmc   +1 more source

Adult Acute Myeloid Leukaemia With <i>DDX3X::MLLT10</i>: A Rare Entity With Significant Unmet Clinical Needs. [PDF]

EJHaem
Ng JY, Sr A, Joshi M, Talaulikar D.
europepmc   +1 more source

Re-treatment of relapse in elderly AML with time-limited venetoclax-based regimen: a case report and literature review. [PDF]

Ann Hematol
Ng JY, Gullapalli V, Othman J, Talaulikar D.   +3 more
europepmc   +1 more source

Case Report: FIA plus venetoclax in a patient on hemodialysis. [PDF]

Front Oncol
Herstein JE, Marx KR, Savoy JM, Jen WY, Yilmaz M, Short NJ, Issa GC, Ravandi F, Kadia TM, Daver NG, DiNardo CD.   +10 more
europepmc   +1 more source

Epigenetic remodeling via HDAC6 inhibition amplifies anti-tumoral immune responses in myeloid leukemia cells. [PDF]

Cell Death Dis
Schliehe-Diecks J, Tu JW, Stachura P, Schaal K, Kemkes M, Vasileiou E, Rüchel N, Brandes D, Vogt M, Lenz T, Nair A, Scheu S, Dominguez PM, Pastorczak A, Nebral K, Stühler K, Fischer U, Pandyra AA, Borkhardt A, Bhatia S.   +19 more
europepmc   +1 more source

Acid ceramidase inhibition enhances BCL-2 targeting in venetoclax-resistant acute myeloid leukemia. [PDF]

Blood Neoplasia
Ung J, Tan SF, Shaw JJP, Taori M, Deddens TM, Venancio G, Montgomery MM, Hagen JT, Aruleba RT, Golla UR, Sharma A, Paudel BB, Lee I, Ramamoorthy B, Janes KA, Garrett-Bakelman F, Cabot MC, Fisher-Wellman KH, Fox TE, Claxton DF, Chalfant CE, Feith DJ, Loughran TP.   +22 more
europepmc   +1 more source

Molecular risk markers define risk of relapse in myeloid leukemia of Down syndrome beyond measurable residual disease. [PDF]

Blood Adv
Berman JN, Verma A, Viola S, Alonzo TA, Wang YC, Brodersen LE, Loken M, Beckman A, Hirsch B, Raimondi S, Chisholm KM, Ma X, Ries R, Meshinchi S, Gamis A, Schore R, Taub JW, Kolb EA, Cooper T, Hitzler J.   +19 more
europepmc   +1 more source

Unveiling and stratifying cell cycle-dependent drug efficacy using a single-cell PLOM-CON approach with correlation anomaly and presage protein signals. [PDF]

Commun Biol
Noguchi Y, Kunishige R, Shinozaki-Narikawa N, Yamashita H, Aihara K, Murata M, Kano F.   +6 more
europepmc   +1 more source

CPX-351 and the Frontier of Nanoparticle-Based Therapeutics in Acute Myeloid Leukemia. [PDF]

Int J Mol Sci
Konstantinidis I, Tsokkou S, Keramas A, Gavriilaki E, Delis G, Papamitsou T.   +5 more
europepmc   +1 more source

CPX-351 in Down syndrome-associated myeloid leukemia: results and prognostic factors from the phase 3 ML-DS 2018 trial.

Blood
Laszig S, Diederichs A, Salzmann-Manrique E, Schuschel K, Gonçalves-Dias J, Issa H, Miladinovic M, Rettinger E, Wehner S, Kreyenberg H, Bremm M, Hünecke S, Kerp H, Waack-Buchholz K, Thol F, Goemans BF, De Moerloose B, Boztug H, Scheidegger N, Pawińska-Wąsikowska K, Reinhardt D, Klusmann JH.   +21 more
europepmc   +1 more source